Venetoclax & azacitidine for AML in 2020

preview_player
Показать описание
Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, discusses the use of venetoclax and azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Paresh Vyas
  3. Institution: University of Oxford
  4. Event: VJVirtual
  5. Event: ASH 2020
  6. Format: Interview
Рекомендации по теме
AML: Managing AEs 0:06:51

AML: Managing AEs With Venetoclax + Azacitidine

Evaluating long-term survival 0:01:56

Evaluating long-term survival in patients with AML who discontinued azacitidine-venetoclax

Venetoclax & azacitidine 0:01:22

Venetoclax & azacitidine for AML in 2020

Venetoclax and azacitidine 0:01:57

Venetoclax and azacitidine for AML ineligible for standard induction

Venetoclax and azacitidine 0:02:49

Venetoclax and azacitidine for young patients with AML

Venetoclax + azacitidine 0:02:43

Venetoclax + azacitidine in unfit patients with AML

AML: Optimizing Selection 0:04:59

AML: Optimizing Selection and Use of Venetoclax + Azacitidine

Venetoclax plus azacitidine 0:01:48

Venetoclax plus azacitidine in FLT3-mutated AML

Anti-tumor Effect of 0:02:20

Anti-tumor Effect of Antibody Drug With Venetoclax Plus Azacitidine in AML | Oncotarget

Venetoclax and azacitidine 0:01:40

Venetoclax and azacitidine in older patients with AML

Venetoclax + Azacitidine 0:07:01

Venetoclax + Azacitidine in Frontline AML Management

IMGN632 plus venetoclax 0:02:45

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AML

Can Venetoclax plus 0:04:23

Can Venetoclax plus Azacitidine Help AML Patients Ineligible for Intensive Treatment?

Phase II study 0:03:40

Phase II study of venetoclax and azacitidine vs induction chemotherapy in fit patients with AML

Venetoclax and Azacitidine 0:03:10

Venetoclax and Azacitidine in Newly Diagnosed AML Patients | Dan Pollyea, MD, MS | ASH 2022 #AML

allo-SCT improves survival 0:02:16

allo-SCT improves survival following venetoclax and azacitidine therapy in AML

Low-dose azacitidine and 0:02:27

Low-dose azacitidine and venetoclax as maintenance therapy in patients with AML

Outcomes of patients 0:02:17

Outcomes of patients with monocytic AML treated with venetoclax & azacitidine

Pevonedistat, venetoclax and 0:02:50

Pevonedistat, venetoclax and azacitidine for older AML patients

Azacitidine, venetoclax & 0:02:44

Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-mutated AML

Phase I trial 0:01:33

Phase I trial results for oral azacitidine and venetoclax in R/R AML

Venetoclax plus azacitidine 0:06:58

Venetoclax plus azacitidine for higher-risk MDS

Jacqueline Garcia: Evaluating 0:06:53

Jacqueline Garcia: Evaluating Venetoclax Plus Azacitidine in Patients with High-Risk MDS

The challenge of 0:01:50

The challenge of treating elderly patients with AML with venetoclax plus azacitidine